Clinical trial

Efficacy of Oocyte Activation With Two Types of Ca2+ Ionophore: a Prospective Randomized Study.

Name
2303-VLC-043-MD
Description
This study is a prospective ranzomized analysis including 372 human oocytes from 44 women. Half of the oocytes from the same patient will be randomly allocated to induce oocyte activation using two protocols: in protocol nº 1 we will use ionomycin (prepared solution), protocol nª2 A23187 (GM508 CultActive Gynemed) will be applied. Non treated oocytes will serve as control. Oocyte fertilization rates, embryo development and embryo quality will be analyzed. Obstetrics variables of offspring will be also followed and compared.
Trial arms
Trial start
2024-01-01
Estimated PCD
2024-12-01
Trial end
2024-12-01
Status
Recruiting
Treatment
Ionomycin SIGMA
Oocytes will be activated with Ionomycin SIGMA
Arms:
GROUP 1 IONOMYCIN SIGMA
A23187
Oocytes will be activated with A23187
Arms:
GROUP 2 A23187
Size
44
Primary endpoint
Improvement in the percetage of usable blastocyst per injeected oocyte
1 YEAR
Eligibility criteria
Inclusion Criteria: * Own oocyte patients who have had previous fertilization failure in previous cycles. * Own oocyte patients with fertilization rate in previous cycles less than or equal to 30% of the microinjected oocytes. Exclusion Criteria: * Oocyte Recipient Patients * Sperm bank sperm recipient patients * Patients who after oocyte decumulation have less than 2 mature oocytes.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Prospective ranzomized analysis', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 44, 'type': 'ESTIMATED'}}
Updated at
2024-03-13

1 organization

2 products

2 indications

Product
Ionomycin
Indication
infertility
Indication
Woman
Product
A23187